| CAS NO: | 10236-47-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| 50g | 电议 |
| Molecular Weight (MW) | 580.53 |
|---|---|
| Formula | C27H32O14 |
| CAS No. | 10236-47-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 116 mg/mL (199.8 mM) |
| Water: 2 mg/mL (9.1 mM) | |
| Ethanol: 2 mg/mL (3.4 mM) | |
| Other info | Chemical Name: 7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one InChi Key: DFPMSGMNTNDNHN-JJLSSNRUSA-N InChi Code: InChI=1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16?,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1 SMILES Code: O=C1CC(C2=CC=C(O)C=C2)OC3=C1C(O)=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)=C3 |
| Synonyms | Naringoside; AI319008; Aurantiin; AI3-19008; AI3 19008; Naringin |
| In Vitro | In vitro activity: Naringin (also known as Naringoside) is a flavanone glycoside analog that exerts a wide range of pharmacological effects such as antioxidant activity, blood lipid lowering, anticancer activity, and inhibition of cytochrome P450 enzymes. Naringin is the substance that gives the grapefruit juice its bitter taste.It inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions. Naringin is also an inhibitor of vascular endothelial growth factor (VEGF) release, which causes angiogenesis. In addition, Naringin reduces diabetes-induced neuropathy in rats. Cell Assay: HBZY-1 cells are plated into 96-well plates and pretreated with various concentrations(1, 5, 10, 25, 50, 100 μM) of naringin for 2 h. Then cells are treated with 30 mM glucose for 24 h. The control group is added sterile normal saline in the same volume. After treatment, all the wells are incubated with 20 μL of 5 mg/ml MTT for 4 h at 37°C. Subsequently, 100 μL of DMSO are used to dissolve the formed formazan crystals after removal of the supernatant. The result is recorded at 490 nm on a microplate reader |
|---|---|
| In Vivo | Naringin reduces diabetes-induced neuropathy in rats. |
| Animal model | Rats and mice |
| Formulation & Dosage | Rats: The rats are randomly divided into six groups: control, naringin (80 mg/kg), STZ, STZ+naringin (20 mg/kg), STZ+naringin (40 mg/kg), STZ+naringin(80 mg/kg). The rats in the STZ and STZ+naringin groups are intraperitoneally injected with STZ (65 mg/kg). The control and naringin groups are intraperitoneally injected with 0.1 M citrate buffer of same volume. After injection of STZ for 3 and 5 days, blood glucose levels are measured by tail vein puncture blood sampling. Mice: Sixty 4-week-old male mice are randomized into four groups and fed for 20 weeks with either control diet or high-fat diet chow. Mice are dosed with 100 mg/kg of naringin daily. Mice body weight and food intake are weekly measured. Following behavioral assessment, animals are deeply anesthetized with isoflurane and sacrificed by decapitation after fasting for at least 5 h. Their plasma is collected for further analysis. |
| References | Life Sci. 1999;65(24):2591-602; J Nutr. 2006 Jun;136(6):1477-82. |
m.cnreagent.com